Raymond Tabibiazar
Präsident bei Aravive Biologics, Inc.
Profil
Dr. Raymond Tabibiazar, MD, is a Managing Director & Director at 526 Ventures LLC and a President & Director at Aravive Biologics, Inc. He is on the Board of Directors at 526 Ventures LLC and Aravive Biologics, Inc.
Dr. Tabibiazar was previously employed as a SVP-Corporate Development & Business Strategy by Twist Bioscience Corp., an Executive Chairman by Aravive Biologics, Inc., a Chief Scientific Officer by Aviir, Inc., a Vice President-Translational Research by VIA Pharmaceuticals, Inc., an Independent Non-Executive Director by Aravive, Inc., a Venture Partner by Bay City Capital LLC, and a Chairman & Chief Executive Officer by SalioGen Therapeutics, Inc. He also served on the board at Versartis, Inc.
He received his doctorate degree from Harvard Medical School.
Aktive Positionen von Raymond Tabibiazar
| Unternehmen | Position | Beginn |
|---|---|---|
| 526 Ventures LLC | Direktor/Vorstandsmitglied | - |
Aravive Biologics, Inc.
 Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Präsident | - |
FORM Life Ventures
 FORM Life Ventures Investment ManagersFinance FORM Life (FORM Life ventures) is venture capital firm founded in 2022 by Markus Okumus. FORM Life Ventures is headquartered in Luxembourg. | Berater | - |
Ehemalige bekannte Positionen von Raymond Tabibiazar
| Unternehmen | Position | Ende |
|---|---|---|
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Vorstandsvorsitzender | 11.09.2023 |
| ARAVIVE, INC. | Vorsitzender | - |
| TWIST BIOSCIENCE CORPORATION | Corporate Officer/Principal | 01.04.2019 |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Vorstandsvorsitzender | 01.05.2017 |
Aviir, Inc.
 Aviir, Inc. Medical/Nursing ServicesHealth Services Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA. | Gründer | 01.10.2007 |
Ausbildung von Raymond Tabibiazar
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| VIA PHARMACEUTICALS, INC. | Health Technology |
| ARAVIVE, INC. | Health Technology |
| TWIST BIOSCIENCE CORPORATION | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
Aravive Biologics, Inc.
Aravive Biologics, Inc. Pharmaceuticals: MajorHealth Technology Aravive Biologics, Inc. develops novel targeted therapeutics in oncology. The company was founded by Amato Giaccia and Albert Koong and is headquartered in Houston, TX. | Health Technology |
Aviir, Inc.
Aviir, Inc. Medical/Nursing ServicesHealth Services Aviir, Inc. discovers, develops and commercializes diagnostic laboratory tests for cardiovascular diseases. The biotechnology company specializes in developing proprietary diagnostic tests to assist in identifying patients who are truly at high risk for the development of a cardiac event. The company was founded in 2005 and is headquartered in Irvine, CA. | Health Services |
Versartis, Inc.
 Versartis, Inc. Pharmaceuticals: MajorHealth Technology Versartis, Inc. is an endocrine-focused biopharmaceutical company, which engages in the research and development of pharmaceutical products. Its portfolio includes Somavartan and XTEN TEchnology which target the endocrine disorders and growth hormone deficiencies. The company was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Menlo Park, CA. | Health Technology |
| 526 Ventures LLC | |
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Health Technology |
FORM Life Ventures
FORM Life Ventures Investment ManagersFinance FORM Life (FORM Life ventures) is venture capital firm founded in 2022 by Markus Okumus. FORM Life Ventures is headquartered in Luxembourg. | Finance |
